 Strong balance sheet with approximately 27.9 million in cash and cash equivalents Strengthened the Companys veterinary leadership team to drive commercial focus Expanded the Companys intellectual property portfolio Published two clinical papers Continued focus on, and made strong progress towards, product launches and licensing in both the human and veterinary spaces worldwide AUSTIN, Texas, Aug. 11, 2021 PRNewswire -- VolitionRx Limited NYSE AMERICAN: VNRX Volition today announced financial results and a business update for the second quarter ended June 30, 2021. Volition management will host a conference call tomorrow, August 12 at 8:00 a.m. 